journal logo
  • search
  • open the menu

Intro Pullout Text Widget

Annals of the Rheumatic Diseases (ARD)

is an official journal of EULAR and the home for innovative rheumatology research.
EULAR logo

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

ARD is an official journal of EULAR.

Free lay summaries are provided for selected research articles and all EULAR recommendations. You can keep up with the latest news via Twitter and Facebook.

Podcast iconListen to the ARD podcast and subscribe in all podcast platforms, including Apple Podcast, Google Podcasts, Stitcher and Spotify.

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

COVID-19: a message from BMJ >>

Latest Content
Impact Factor
16.102
Annals of the Rheumatic Diseases

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.
 
The Author Information section provides general guidelines and requirements for specific article types.
 
Information is also provided on editorial policies and open access.

In the news: tocilizumab and COVID-19

Reports that the use of the rheumatoid arthritis drug tocilizumab can reduce the risk of death from COVID-19 have been widely circulated. 

 

ARD published a paper back in July 2020 on this topic: Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.

 

This study showed that a course of high-dose methylprednisolone, followed by tocilizumab if needed, may accelerate respiratory recovery, lower hospital mortality and reduce the likelihood of invasive mechanical ventilation in COVID-19-associated cytokine storm syndrome.

 

The paper is free to access. There is also an associated video abstract and audio podcast.

 

EULAR Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field. All EULAR recommendations are free to access. 

 

The January 2021 issue of ARD contains the latest recommendations, including:

 

Prevention and management of fragility fractures in adults 50 years or older

Diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors

Definition of difficult-to-treat rheumatoid arthritis

A core data set for pregnancy registries in rheumatology

Assessment of competences in rheumatology specialty training

 

 

Altmetrics

Podcasts